Evidence map›Paper›PMID 34249905›Full record

ArticleFrontiers in cell and developmental biology2021

Andrographolide Suppresses the Growth and Metastasis of Luminal-Like Breast Cancer by Inhibiting the NF-κB/miR-21-5p/PDCD4 Signaling Pathway.

Junchen Li, Lixun Huang, Zinan He, Minggui Chen, Yi Ding, Yuying Yao, Youfa Duan, Li Zixuan, Cuiling Qi, Lingyun Zheng and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025
    Review
  8. A new era of cancer immunotherapy: vaccines and miRNAs.Cancer immunology, immunotherapy : CII · 2025
    Review
  9. Diterpenes: Nature's Hidden Gems of Immunomodulation.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Review
  12. Identification and validation of an immune-derived multiple programmed cell death index for predicting clinical outcomes, molecular subtyping, and drug sensitivity in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  13. Article
  14. Article
  15. Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  16. Article
  17. BioMedicine · 2024
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Junchen LiSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Lixun HuangSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Zinan HeSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Minggui ChenSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Yi DingSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Yuying YaoSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Youfa DuanSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Li ZixuanSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Cuiling QiSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Lingyun ZhengSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Jiangchao LiSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Rongxin ZhangSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Xiaoming LiDepartment of Pathology, People's Hospital of Baoan District, Affiliated Baoan Hospital of Shenzhen, Southern Medical University, The Second Affiliated Hospital of Shenzhen University, Shenzhen, China.
Jianwei DaiGuangzhou Medical University-Guangzhou Institute of Biomedicine and Health (GMU-GIBH) Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China.
Lijing WangSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Qian-Qian ZhangSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China.
Guangdong Pharmaceutical University · CNGuangzhou Medical University · CNShenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor growth and metastasis are responsible for breast cancer-related mortality. Andrographolide (Andro) is a traditional anti-inflammatory drug used in the clinic that inhibits NF-κB activation. Recently, Andro has been found in the treatment of various cancers. Andro inhibits breast cell proliferation and invasion and induces apoptosis

Indexed as

andrographolidegrowthluminal-like breast cancermetastasisNF-κB/miR-21-5p/PDCD4 signaling pathway

Identifiers

PMID34249905
PMCPMC8261247
OpenAlexW3176529968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.